IFN-α, drives dendritic cell activation, autoreactive B cell survival, and tissue inflammation in SLE. By blocking IFN-α, sifalimumab sought to decrease disease flares, lower autoantibody levels, and improve clinical outcomes, particularly in patients with high baseline interferon signaling.